Pasar al contenido principal

NUEVOS ANTIVIRALES MEDIANTE DISEÑO BASADO EN LA ESTRUCTURA DE PROTEINAS CLAVE EN LA INFECCION POR EL VIRUS DEL NILO OCCIDENTAL Y OTROS FLAVIVIRUS RELACIONADOS

PID2019-105117RR-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Efficient blocking of Sars-CoV-2 entry through tryptophan derivatives interfering with the interaction of Ace2 with the viral spike

  • Gargantilla, Marta
  • Francés-Gómez, Clara
  • Adhav, Anmol
  • Martínez-Gualda, Belén
  • Marina, Alberto
  • Rubio, Vicente
  • San-Félix, Ana
  • Peréz-Pérez, María-Jesús
  • Geller, Ron
Resumen del póster presentado al International Symposium on Medicinal Chemistry, celebrado en Niza (Francia) del 4 al 8 de septiembre de 2022., The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the largest pandemic the world has suffered in recent years, COVID-19.1 Coronaviruses are characterized by spike proteins that are crucial for the entry process into the host cells. Particularly, the spike protein of SARS-CoV-2 binds to the human angiotensin converting enzyme 2 (ACE2) through its receptor binding domain (RBD) (Figure 1), leading to viral entry and subsequent infection of the host cell.1,2 Thus, inhibition of SARS-CoV-2 by blocking the interaction of the spike protein with ACE2 represents an appealing antiviral strategy that can be combined with the treatments already approved. Our research group has been extensively involved in the search for entry inhibitors of different virus, as recently reported for potent HIV and EV-A71 antivirals.3 In the current project, 200 compounds were evaluated as entry inhibitors in a HTS assay using VSV pseudoparticles expressing the SARS-CoV-2 spike protein in Vero cells. The identified hits, with a tryptophan scaffold, have been further explored through the synthesis of structural analogues. As a result, we have identified compounds able to block viral entry in the pseudoparticles assay with IC50 values in the low micromolar or submicromolar range and in the absence of toxicity to host cells (CC50>100 µM). Moreover, their antiviral activity has been confirmed against SARS-CoV-2 in Vero E6 and A549-ACE2 cells. Additionally, biophysical studies using microscale thermophoresis have evidenced that these compounds are able to interact with the RBD and spike of SARS-CoV-2 and significantly affect the KD of the interaction of the RBD with ACE2. Thus, these compounds represent an interesting alternative for the development of SARS-CoV-2 therapies and/or prevention., This research has been funded by Fondo Supera COVID-19 (Crue-CSIC-Santander), by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global) and by PID2019-105117RR-C22/ AEI / 10.13039/501100011033., No